BHRC BLOG
The FDA Is Reconsidering Its Peptide Ban: What This Means for Your Health
A major shift in peptide regulation may be on the horizon. In late February 2026, Health Secretary Robert F. Kennedy Jr. revealed that the FDA is preparing to loosen restrictions on over a dozen previously banned peptides, potentially moving them from the agency’s category 2 list back to category 1. As featured in a recent GQ article on the peptide recategorization, Beverly Hills Rejuvenation Center’s own Chief Innovation Officer Sanjiv Lal weighed in on what this means for patients and the future of peptide medicine.
For the millions of Americans who have been following the peptide conversation, or who relied on these compounds before they were restricted, this is significant news. But it also raises important questions about safety, access, and what responsible peptide therapy actually looks like.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. All peptide therapy requires physician supervision, comprehensive health assessment, and individualized treatment protocols. Consult with a qualified healthcare provider before starting any peptide therapy.
BHRC Featured in GQ Magazine
In a March 2026 GQ feature titled “It’s About to Be Hot Peptide Summer,” BHRC Chief Innovation Officer Sanjiv Lal was interviewed alongside leading physicians and healthcare executives about the future of peptide regulation in the United States.
“The debate isn’t about whether peptides work. It’s about which ones have enough evidence and regulatory oversight around them.”
— Sanjiv Lal, Chief Innovation Officer, Beverly Hills Rejuvenation Center | as quoted in GQ
This perspective captures the balanced approach BHRC has maintained throughout the evolving peptide landscape: embracing innovation while prioritizing patient safety and evidence-based care.
What Happened: The FDA’s Category 2 Peptide List
In recent years, the FDA placed 19 peptides on its category 2 list, effectively banning compounding pharmacies from formulating them and restricting physicians from prescribing them. This decision impacted compounds that many patients had been using under medical supervision for conditions related to inflammation, gut health, metabolism, cognition, and recovery.
The peptides affected included some of the most widely discussed compounds in regenerative and functional medicine, such as BPC-157, TB-500, and DSIP. For patients who had been experiencing clinical benefits from these therapies, the ban meant either going without treatment or turning to unregulated sources, neither of which is ideal.
Now, with approximately 14 of these peptides expected to be moved back to category 1, the door is reopening for physician-prescribed, pharmacy-compounded peptide therapy.
What Recategorization Actually Means
It is important to understand what this regulatory shift does and does not change. Moving peptides from category 2 to category 1 means:
- Compounding pharmacies will again be able to formulate these peptides for patient use
- Physicians will be able to prescribe them as part of supervised treatment plans
- Research institutions will have greater ability to conduct clinical studies on these compounds
- FDA-inspected facilities will handle manufacturing, reducing reliance on unregulated sources
What it does not mean is that these peptides will be available over the counter. They will still require a physician’s prescription, medical oversight, and individualized dosing, as they should.
Opening the Door to Better Research
One of the most compelling arguments for recategorization is the impact on scientific research. When peptides sit on the category 2 list, it drastically limits the type of research that can be conducted. Moving them to category 1 opens the door to more rigorous clinical trials, better safety data, and a deeper understanding of how these compounds work in the human body.
Consider the trajectory of peptides we already know well. Insulin, a peptide, transformed diabetes care. Semaglutide, tirzepatide, and retatrutide, all peptides, are reshaping the treatment of obesity. The potential locked within the compounds currently on the category 2 list is enormous, but it can only be realized through proper clinical investigation.
As Sanjiv Lal noted in GQ, the core question has never been whether peptides work. The question is which ones have sufficient evidence and oversight. Recategorization creates the conditions for researchers to answer that question with the rigor these compounds deserve.
Why Physician-Guided Peptide Therapy Matters More Than Ever
The restriction of these peptides did not eliminate demand. If anything, it pushed more people toward unregulated online sources, a gray and black market where quality control, dosing accuracy, and sterility are far from guaranteed. A return to category 1 means patients can once again access these compounds through legitimate, FDA-inspected channels under the guidance of experienced physicians.
This is critical because peptide therapy is not a one-size-fits-all endeavor. These compounds require:
- Specific cycling protocols tailored to each patient’s goals and health status
- Precise dosing based on individual factors such as body composition, medical history, and treatment objectives
- Ongoing monitoring to assess efficacy, watch for side effects, and adjust treatment as needed
- Risk-benefit analysis conducted by a physician who understands the latest research
At Beverly Hills Rejuvenation Center, this is exactly the kind of care our patients receive. Our medical team evaluates each individual’s needs, designs personalized protocols, and provides the ongoing oversight that responsible peptide therapy demands.
Key Peptides That May Return to Category 1
While the official list of reclassified peptides has not yet been announced, the following compounds have been among the most discussed in the context of this regulatory shift. Many of these are peptides that BHRC has extensive clinical experience with:
BPC-157 (Body Protection Compound)
Often called the “Wolverine peptide” for its potential regenerative properties, BPC-157 has been one of the most sought-after compounds in functional medicine. It is primarily studied for its role in supporting tissue repair, gut health, and inflammatory response. While animal studies have shown promising results, human clinical trials remain limited, which is precisely why recategorization and the research it enables are so important.
TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment of the naturally occurring protein thymosin beta-4, which plays a role in cell migration, blood vessel formation, and tissue repair. It has generated significant interest for its potential applications in recovery from injury and supporting musculoskeletal health.
DSIP (Delta Sleep-Inducing Peptide)
DSIP is a neuropeptide that has been studied for its potential effects on sleep regulation, stress response, and neuroendocrine function. For patients dealing with sleep disturbances or chronic stress, DSIP has been an area of particular interest in integrative medicine.
BHRC also offers a comprehensive range of peptides that are currently available and have established safety and efficacy profiles, including semaglutide for weight management, sermorelin and ipamorelin for growth hormone optimization, and many more. View our full peptide menu to explore what is available today.
What You Should Do Right Now
If you have been following the peptide conversation or are interested in exploring peptide therapy, here is practical guidance:
1. Educate Yourself
Understanding what peptides are, how they work, and what the research does and does not support is the foundation of making informed decisions about your health. Browse our peptide therapy resources for evidence-based information on available compounds.
2. Find a Trusted Provider Now
Do not wait until these peptides become available to start looking for a physician. As experts noted in the GQ article, if someone claims to have these peptides available immediately after an announcement, that is a red flag. The manufacturing, testing, and quality assurance process takes weeks to months. Use this time to establish a relationship with a provider you trust.
3. Be Cautious of Unregulated Sources
Until these peptides are officially reclassified and available through legitimate compounding pharmacies, resist the temptation to obtain them through unverified channels. The risks of contamination, incorrect dosing, and counterfeit products are real and potentially dangerous.
4. Schedule a Consultation
The best way to determine whether peptide therapy is right for you is through a comprehensive consultation with a qualified physician. At BHRC, our medical team can evaluate your health goals, review your medical history, and recommend a personalized approach, whether that involves currently available peptides or preparing for newly recategorized options when they become accessible.
BHRC’s Commitment to Safe, Evidence-Based Peptide Therapy
At Beverly Hills Rejuvenation Center, peptide therapy has been a core part of our treatment offerings for years. Our approach has always been grounded in the same philosophy that Sanjiv Lal expressed in GQ: the debate is not about whether peptides work, it is about ensuring that the ones we use have sufficient evidence and regulatory oversight.
As the regulatory landscape evolves, BHRC is positioned to be at the forefront of this new chapter in peptide medicine. Our team stays current with the latest research, works exclusively with FDA-inspected compounding pharmacies, and maintains the rigorous medical oversight that peptide therapy requires.
Whether you are new to peptides or have been exploring them for years, we are here to guide you with the expertise and care that this nuanced area of wellness demands.
Ready to Explore Peptide Therapy?
Schedule a consultation with our medical team to discuss your health goals and learn which peptide therapies may be right for you.
Continue Learning About Peptides
Explore our comprehensive peptide resources to learn more about specific compounds, their mechanisms, and how they may support your health goals:
- BPC-157: The Body Protection Compound
- TB-500: Thymosin Beta-4 Fragment
- DSIP: Delta Sleep-Inducing Peptide
- Semaglutide for Weight Management
- Tirzepatide
- Retatrutide
- View All Peptide Therapies at BHRC
Beverly Hills Rejuvenation Center offers peptide therapy at locations nationwide. To find a BHRC location near you, visit bhrcenter.com/locations.
